Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services
Novotech, the global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been awarded the prestigious 2024 Global Company of the Year Award by Frost & Sullivan. This recognition underscores Novotech’s commitment to accelerating clinical development for biotech companies through innovative solutions, advanced analytics, and a comprehensive global reach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910876910/en/
(Graphic: Business Wire)
Frost & Sullivan’s award honors Novotech’s innovative full-service approach that accelerates clinical development through advanced analytics, access to diverse patient populations, and through specialized technology.
“Overall, Novotech distinguishes itself in the ever-expanding CRO market by successfully addressing the complex regulatory landscape with a deep understanding of local regulations and overcoming cultural barriers to establish itself as a truly global CRO. As a result, the company progresses closer to becoming a preferred global partner with regional leadership and localized expertise,” said Unmesh Lal, Global Research Director at Frost & Sullivan.
Unmatched Global Reach and Expertise
Novotech's extensive global footprint allows the company to provide tailored solutions that address the unique regulatory and cultural nuances of each market. This strategic advantage facilitates faster patient recruitment and enhanced trial efficiency, ensuring successful outcomes for its biotech clients. Novotech's project manager-centric model ensures seamless communication and effective execution of clinical trials, fostering strong, collaborative relationships with clients.
Commitment to Innovation and Advanced Technology
A key element in being awarded this accolade is Novotech continuing to leverage cutting-edge technology to enhance clinical trial operations. The company's ongoing investments in artificial intelligence (AI), big data analytics, digital clinical trials, and cloud-based software platforms significantly improve data quality, trial planning, and transparency in communications with stakeholders. Partnerships with industry leaders like Veeva and Medidata further empower Novotech’s clients to optimize their drug development programs.
Recognition of Excellence
Frost & Sullivan first recognized Novotech with their award for best APAC CRO in 2006, and Novotech has continued to win this award every year since. Receiving, for the first time, Frost & Sullivan’s 2024 Global Company of the Year Award is tangible evidence of Novotech’s drive for constant improvement and creating optimal outcomes for our partners and clients.
“We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan,” said Dr. John Moller, CEO of Novotech. “This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the CRO industry.”
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910876910/en/
Contacts
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Announce Third Quarter 2024 Financial Results on November 4 th10.10.2024 23:05:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, li
Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders10.10.2024 17:17:00 EEST | Press release
Cognite,the Data and AI authority for industry, today announced the launch of Cognite Embedded. This new offering enables Original Equipment Manufacturers (OEMs) and Industrial Software Vendors (ISVs) to accelerate time to market, drastically reduce total cost of ownership, and future-proof their digital solutions with AI-ready architectures, all through Cognite’s leading industrial data platform, Cognite Data Fusion, and low-code industrial agent workbench, Cognite Atlas AI ®. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009752580/en/ Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders (Photo: Business Wire) Integrating and contextualizing data is often the biggest hurdle for OEMs and ISVs. Additionally, they need to onboard new customers and roll out data-driven solutions without the high costs associated with maintaining complex custom infrastructu
KAGA FEI Develops Ultra-small Bluetooth Low Energy Module Compatible with Bluetooth 6.010.10.2024 17:00:00 EEST | Press release
KAGA FEI Co., Ltd., a global provider of leading short distance wireless modules, announced today the ES4L15BA1 Bluetooth Low Energy module. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010420482/en/ ES4L15BA1 (Photo: Business Wire) The module has a built-in antenna and has obtained various certifications. Consequently, it reduces the development time and certification costs for next-generation wireless IoT products such as IoT devices, small medical/healthcare products, and wearable devices that require a compact form factor, enabling faster time-to-market. The ES4L15BA1 also supports channel sounding for accurate distance measurement, providing further convenience for applications requiring reliable distance information or enhanced security based on device distance information, such as unlocking devices based on their proximity. Furthermore, it supports PSA*1 certification, making it easier to develop IoT devices that
Vespa.ai Announces Support for ColPali in Retrieval Augmented Generation (RAG)10.10.2024 16:00:00 EEST | Press release
Vespa.ai, developer of the leading platform for AI applications including Retrieval-Augmented Generation (RAG), has today announced support for ColPali, a new open-source retrieval model for visually rich documents such as PDFs. ColPali enhances document retrieval by embedding entire rendered documents, including visual elements, into vector representations optimized for Large Language Models (LLMs). This reduces latency, improves accuracy, and enables more context-aware information retrieval, especially for visually rich content. By treating documents as visual entities rather than text, ColPali eliminates complex preprocessing, preserves visual context, and streamlines the RAG pipeline. Jon Bratseth, CEO and Founder, Vespa.ai: “With ColPali’s capabilities, combined with our scalable architecture and hybrid search, Vespa.ai delivers the fastest and most accurate solution for large-scale RAG and generative AI applications. Vespa is available as a service to simplify deployment further.
1NCE Has Another Record Year and Boosts Executive Team10.10.2024 15:15:00 EEST | Press release
1NCE, a company offering a software platform for connected products, today announced appointments and promotions for its executive team: Sven Adler as Chief Financial Officer, Arne Aßmann as Chief Strategy Officer, Jennifer Haag as Chief Human Resources Officer, Nicolas Martinez-Fresno as Chief Sales and Marketing Officer and Ivo Rook as Co-Chief Executive Officer. Founder Alexander P. Sator will continue as Co-Chief Executive Officer of 1NCE, focusing on corporate development while Rook focuses on guiding the company leadership team in delivering growth, quality operations and relentless execution. The company’s unique business model, powered by a strong investor base including major network operators like Deutsche Telekom and SoftBank, has positioned 1NCE as one of the fastest growing companies in the marketplace. 1NCE’s platform is increasingly recognized as a global standard in IoT, with more than 23,000 customers from 52 countries collecting data from 30 million managed endpoints
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom